Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours
1990

Pharmacokinetics of Etoposide in Cancer Treatment

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): B. Desoizel, F. Marechall, A. Cattan

Primary Institution: Institut Jean Godinot

Hypothesis

The study investigates the relationship between etoposide plasma concentration and treatment efficacy in patients with solid tumors.

Conclusion

The study found that higher etoposide plasma concentrations were associated with better treatment responses in cancer patients.

Supporting Evidence

  • Etoposide plasma concentration was significantly higher in responders compared to non-responders.
  • Creatinine clearance was correlated with etoposide concentration and efficacy.
  • Six out of seven non-responders had low plasma concentrations of etoposide.

Takeaway

Doctors studied how a cancer drug called etoposide works in the body and found that higher amounts of the drug in the blood helped some patients get better.

Methodology

The pharmacokinetics of etoposide were studied in 14 patients with solid tumors over 32 treatment courses, measuring plasma concentrations and correlating them with treatment responses.

Limitations

The study did not account for the effects of other chemotherapy drugs on efficacy.

Participant Demographics

Patients included 10 with non-small cell lung cancer, 1 with non-Hodgkin's lymphoma, 1 with breast cancer, and 2 with unknown primary cancer.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication